To assess the effectiveness of minimally invasive glaucoma surgery (MIGS) as monotherapy, or in combination with phacoemulsification, in the management of normal tension glaucoma (NTG). A systematic literature review and meta-analysis were conducted. The literature search was performed using four electronic databases, including Pubmed, Embase, Web of science, and Cochrane Central Register of Controlled Trials, to identify studies evaluating the efficacy of MIGS on patients with NTG, published from October 1, 2019 to October 1, 2024. The articles meeting our inclusion criteria were independently screened and assessed by three reviewers. Effect estimates associated with NTG were pooled and evaluated via meta-analysis. The articles retrieved from the databases were systematically analyzed using Citespace 6.2.R3. A total of 11 English-language studies involving 413 eyes from 327 NTG patients were included. Follow-up ranged from 6 to 60 months. MIGS alone reduced IOP by 2.62 mmHg (95% CI: -3.70 to -1.54; Z = 4.77, P < 0.00001), while MIGS with cataract surgery reduced IOP by 2.09 mmHg (95% CI: -2.83 to -1.35; Z = 5.53, P < 0.00001). The number of IOP-lowering medications decreased by 1.47 with MIGS alone (95% CI: -2.16 to -0.77; Z = 4.07, P < 0.0001) and by 1.13 with combined surgery (95% CI: -1.75 to -0.52; Z = 3.63, P = 0.0003). No significant differences were observed between the two surgical approaches. The meta-analysis demonstrated that either MIGS alone or combined with phacoemulsification effectively reduced the IOP and the requirement for IOP-lowering medications in NTG patients. MIGS alone or combined with phacoemulsification reduced the IOP most at 12 months, and the lowest IOP-lowering medications at 24 months in postoperative patients with NTG. Normal-tension glaucoma (NTG), a subtype of primary open-angle glaucoma (POAG), is characterized by optic nerve damage despite intraocular pressure (IOP) within the statistically normal range. Microinvasive glaucoma surgery (MIGS), with its minimal invasiveness, safety profile, and compatibility with phacoemulsification, presents a promising alternative for NTG management. However, prior evidence on the efficacy and safety of MIGS in NTG patients was limited and fragmented. This study aimed to systematically evaluate the long-term outcomes of MIGS alone or combined with phacoemulsification in reducing IOP and medication burden in NTG patients, addressing critical knowledge gaps in this understudied population. The hypothesis of this study is that Both MIGS alone and MIGS combined with phacoemulsification would achieve significant reductions in IOP and medication use in NTG patients. Combined surgery was hypothesized to offer additional benefits (e.g., addressing concurrent cataracts) without compromising safety. The meta-analysis demonstrated that MIGS alone or combined with phacoemulsification effectively reduced the IOP and the requirement for IOP-lowering medications in postoperative patients with NTG. MIGS with phacoemulsification failed to improve IOP and IOP-lowering medications more than MIGS alone. MIGS alone or combined with phacoemulsification reduced the IOP most at 12 months, and the lowest IOP-lowering medications at 24 months in postoperative patients with NTG. Both MIGS alone and combined with phacoemulsification effectively reduced IOP and medication requirements in NTG patients, with comparable efficacy. Combined surgery is advantageous for NTG patients with concurrent cataracts, preventing postoperative cataract progression and reducing reoperation risks. This study tells us that phacoemulsification alone or in combination can effectively reduce the IOP and the need for ocular hypotensive drugs in patients after NTG surgery, and reduce the occurrence of complications. This gives us more confidence to use MIGS surgery on NTG patients to achieve the purpose of anti-glaucoma treatment. In addition, the development and upgrading of existing glaucoma filtering devices will benefit more patients.